ResearcherIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaActive in the last 2 years
Alessandro Cucchetti
Matched on ORCID iD 0000-0001-5269-1964; OpenAlex author ID A5032258617. Sources: OpenAlex.
Their work
- Papers
- 14 (first author 2, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 31
2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 5 papers · 2025: none · 2026: 1 paper
Papers 14
- Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and prognostic values. First author DOI 10.1007/s11547-025-02131-7↗
- Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2024.2485↗
- REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
- Local recurrence rate as quality indicator in surgery for pancreatic cancer? First author DOI 10.1016/j.hbpd.2024.03.003↗
- Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Last author DOI 10.1097/sla.0000000000006166↗
- REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
- European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019. Co-author DOI 10.1016/j.pan.2023.09.001↗
- Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
- Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2022.04.011↗
- Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. Co-author DOI 10.3390/cancers15010001↗
- Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Last author DOI 10.3390/biom11060780↗
- The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2019.06.004↗
- A comprehensive analysis on expected years of life lost due to pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.02.005↗
- Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000523↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giorgio Ercolani · 10 shared papers, 2016–2026 · strength 1.76
- Paper Local recurrence rate as quality indicator in surgery for pancreatic cancer? DOI 10.1016/j.hbpd.2024.03.003↗
- Paper Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and p… DOI 10.1007/s11547-025-02131-7↗
- Paper European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data a… DOI 10.1016/j.pan.2023.09.001↗
- Massimo Falconi · 4 shared papers, 2022–2024 · strength 0.73
- Paper European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data a… DOI 10.1016/j.pan.2023.09.001↗
- Paper Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. DOI 10.1097/sla.0000000000006166↗
- Paper Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. DOI 10.1001/jamasurg.2024.2485↗
- Stefano Crippa · 4 shared papers, 2022–2024 · strength 0.73
- Paper European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data a… DOI 10.1016/j.pan.2023.09.001↗
- Paper Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. DOI 10.1097/sla.0000000000006166↗
- Paper Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. DOI 10.1001/jamasurg.2024.2485↗
- Cecilia Binda · 3 shared papers, 2022–2026 · strength 0.64
- Paper Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and p… DOI 10.1007/s11547-025-02131-7↗
- Paper Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. DOI 10.1016/j.ejso.2022.04.011↗
- Paper Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. DOI 10.3390/cancers15010001↗
- Carlo Alberto Pacilio · 2 shared papers, 2023–2024 · strength 0.56
- Carlo Fabbri · 3 shared papers, 2022–2023 · strength 0.52
- Paper European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data a… DOI 10.1016/j.pan.2023.09.001↗
- Paper Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. DOI 10.1016/j.ejso.2022.04.011↗
- Paper Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. DOI 10.3390/cancers15010001↗
- Giuseppe Malleo · 2 shared papers, 2024 · strength 0.36
- Giulio Belfiori · 2 shared papers, 2024 · strength 0.36
- Fabio Casciani · 2 shared papers, 2024 · strength 0.36
- Riccardo Casadei · 2 shared papers, 2024 · strength 0.36
- Claudio Ricci · 2 shared papers, 2024 · strength 0.36
- Alessandro Ferrero · 2 shared papers, 2024 · strength 0.36
- Serena Langella · 2 shared papers, 2024 · strength 0.36
- Gabriella Lionetto Lionetto · 2 shared papers, 2024 · strength 0.36
- Roberto Salvia · 2 shared papers, 2024 · strength 0.36
- Matteo Renzulli · 1 shared paper, 2026 · strength 0.32
- Emanuela Giampalma · 1 shared paper, 2026 · strength 0.32
- Gabriele Capurso · 1 shared paper, 2023 · strength 0.19
- Carlo Ingaldi · 1 shared paper, 2024 · strength 0.18
- Vincenzo Mazzaferro · 1 shared paper, 2024 · strength 0.18
- Vincenzo D’Ambra · 1 shared paper, 2024 · strength 0.18
- Matteo Serenari · 2 shared papers, 2016–2019 · strength 0.15
- Caterina Vivaldi · 1 shared paper, 2021 · strength 0.13
- Alessandro Passardi · 1 shared paper, 2021 · strength 0.13
- Ilario Giovanni Rapposelli · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.